Condition
Metastatic Melanoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 54 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
54 shownMorning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT StudyNCT07405086 · 2026-06-08
RECRUITINGA Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingNCT06066138 · 2025-11-04
RECRUITINGGene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsNCT04119024 · 2025-10-07
RECRUITINGSafety and Efficacy of OBX-115 in Advanced Solid TumorsNCT06060613 · 2023-10-25
RECRUITINGA Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerNCT05361174 · 2022-07-20
RECRUITINGPersonalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 · 2022-03-31
RECRUITINGCryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialNCT04693377 · 2021-03-16
RECRUITINGAvapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid TumorsNCT04771520 · 2021-01-20
RECRUITINGEvaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer TypesNCT06075524 · 2015-06-15
RECRUITINGAerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the LungNCT05717140 · 2025-10-28
WITHDRAWNTesting Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12
ACTIVE_NOT_RECRUITINGCALM: Managing Distress in Malignant Brain CancerNCT06180460 · 2023-11-10
COMPLETEDIn Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid TumorsNCT04616248 · 2023-01-09
ACTIVE_NOT_RECRUITINGA Study to Investigate 14C-bemcentinib in Healthy Male SubjectsNCT06469138 · 2022-08-02
COMPLETEDQuantifying Systemic Immunosuppression to Personalize Cancer TherapyNCT04941365 · 2022-07-07
WITHDRAWNNOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNtsNCT04960059 · 2022-02-11
COMPLETEDTesting the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22
ACTIVE_NOT_RECRUITINGTocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaNCT04940299 · 2021-09-23
ACTIVE_NOT_RECRUITINGComparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246 · 2021-08-05
TERMINATEDEstablishment of the Human Intestinal and Salivary Microbiota Biobank - Oncologic DiseasesNCT04698161 · 2021-02-25
COMPLETED18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesNCT04752267 · 2021-02-15
COMPLETEDBintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesNCT04789668 · 2021-01-15
TERMINATEDSafety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNCT04140526 · 2020-09-16
ACTIVE_NOT_RECRUITINGA Phase 1-2 Study of ST101 in Patients With Advanced Solid TumorsNCT04478279 · 2020-07-01
ACTIVE_NOT_RECRUITINGSonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsNCT04007744 · 2020-02-13
ACTIVE_NOT_RECRUITINGDose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid TumorsNCT04140500 · 2019-11-11
ACTIVE_NOT_RECRUITINGUCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeNCT03474497 · 2019-05-20
ACTIVE_NOT_RECRUITINGStudy of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 · 2019-05-07
TERMINATEDA Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)NCT03679767 · 2019-01-09
COMPLETEDA Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid TumorsNCT03708328 · 2018-10-15
COMPLETEDAbexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor MalignanciesNCT03590054 · 2018-08-20
COMPLETEDA Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaNCT03445533 · 2018-05-30
TERMINATEDIntravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseNCT03025256 · 2018-05-02
ACTIVE_NOT_RECRUITINGGlembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryNCT03326258 · 2018-04-20
WITHDRAWNA Study of ADXS-NEO Expressing Personalized Tumor AntigensNCT03265080 · 2018-03-28
TERMINATEDRadiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaNCT03297463 · 2018-01-31
WITHDRAWNA Study of ASN007 in Patients With Advanced Solid TumorsNCT03415126 · 2018-01-19
COMPLETEDTrigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaNCT03229278 · 2017-10-03
COMPLETEDCD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With NivolumabNCT03123783 · 2017-07-10
COMPLETEDEvaluation of the NantHealth GPS Cancer Test in Patients With Advanced CancersNCT03073473 · 2017-02-28
TERMINATEDPembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain MetastasesNCT02858869 · 2016-10-04
COMPLETEDA Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerNCT02857270 · 2016-09-29
COMPLETEDThermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal CordNCT02713269 · 2016-08-29
ACTIVE_NOT_RECRUITINGTesting the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerNCT02595866 · 2016-04-04
COMPLETEDPhase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495 · 2015-06-26
TERMINATEDIpilimumab-induced Lung Toxicity: Observational StudyNCT02755233 · 2014-01-01
COMPLETEDThe Jules Bordet Institute Molecular Profiling Program Feasibility TrialNCT01932489 · 2013-12-01
COMPLETEDAerosolized Aldesleukin in Treating Patients With Lung MetastasesNCT01590069 · 2012-06-28
ACTIVE_NOT_RECRUITINGRADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMANCT01497808 · 2011-11-29
COMPLETEDLocal Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic MelanomaNCT01216436 · 2010-01-01
TERMINATEDA Study to Assess PV-10 Chemoablation of Cancer of the LiverNCT00986661 · 2009-10-01
UNKNOWNA Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent MalignanciesNCT00730639 · 2008-10-30
COMPLETEDCombination Therapy of F16IL2 and Paclitaxel in Solid Tumour PatientsNCT01134250 · 2008-08-06
COMPLETEDA Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsNCT00526617 · 2007-08-01
COMPLETEDCommon interventions
Computed TomographyPROCEDURE10Biospecimen CollectionPROCEDURE9PembrolizumabBIOLOGICAL8Magnetic Resonance ImagingPROCEDURE7NivolumabBIOLOGICAL7PembrolizumabDRUG4Positron Emission TomographyPROCEDURE4Quality-of-Life AssessmentOTHER4Stereotactic RadiosurgeryRADIATION4BiopsyPROCEDURE3CyclophosphamideDRUG3IpilimumabBIOLOGICAL3IpilimumabDRUG3Laboratory Biomarker AnalysisOTHER3CarboplatinDRUG2NivolumabDRUG2PaclitaxelDRUG2PemetrexedDRUG2Questionnaire AdministrationOTHER2Stereotactic Body Radiation TherapyRADIATION2TemozolomideDRUG218F-FMAUDRUG1AbemaciclibDRUG1AbexinostatDRUG1ABT-888DRUG1
Leading sponsors
M.D. Anderson Cancer Center
8
Mayo Clinic
4
National Cancer Institute (NCI)
4
Hoffmann-La Roche
2
Iovance Biotherapeutics, Inc.
2
NRG Oncology
2
University of Southern California
2
AbbVie
1
Abramson Cancer Center at Penn Medicine
1
Advaxis, Inc.
1
Anusha Kalbasi
1
Apexigen America, Inc.
1
Asana BioSciences
1
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
1
BerGenBio ASA
1
Trial status mix
COMPLETED20
ACTIVE_NOT_RECRUITING12
RECRUITING9
TERMINATED8
WITHDRAWN4
UNKNOWN1
Phase mix
PHASE135
PHASE218
NA4
PHASE33
EARLY_PHASE11
PHASE41
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.